PharmiWeb.com - Global Pharma News & Resources

Cizzle Biotechnology PLC

Research & Development

Cizzle Biotechnology PLC develops a ground-breaking blood test for early lung cancer detection using the patented CIZ1B biomarker. Originally spun out of the University of York and now listed on the London Stock Exchange, Cizzle aims to shift diagnostic pathways by offering a simple, non-invasive, cost-effective test that enables earlier intervention and improved patient outcomes.